Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Deloitte
Moodys
Express Scripts
Chubb
Merck
Cipla
US Army
Daiichi Sankyo

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021144

« Back to Dashboard

NDA 021144 describes KETEK, which is a drug marketed by Sanofi Aventis Us and is included in one NDA. There is one patent protecting this drug. Additional details are available on the KETEK profile page.

The generic ingredient in KETEK is telithromycin. Additional details are available on the telithromycin profile page.
Summary for 021144
Tradename:KETEK
Applicant:Sanofi Aventis Us
Ingredient:telithromycin
Patents:1
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength400MG
Approval Date:Apr 1, 2004TE:RLD:No
Patent:➤ Sign UpPatent Expiration:Apr 1, 2018Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength300MG
Approval Date:Feb 9, 2005TE:RLD:No
Patent:➤ Sign UpPatent Expiration:Apr 1, 2018Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.

Expired US Patents for NDA 021144

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us KETEK telithromycin TABLET;ORAL 021144-002 Feb 9, 2005 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us KETEK telithromycin TABLET;ORAL 021144-002 Feb 9, 2005 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us KETEK telithromycin TABLET;ORAL 021144-001 Apr 1, 2004 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us KETEK telithromycin TABLET;ORAL 021144-001 Apr 1, 2004 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Deloitte
Fuji
Boehringer Ingelheim
Argus Health
Harvard Business School
AstraZeneca
Teva
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.